| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 0.02 | 75.0% |
| Total Income | 0.02 | 75.0% |
| Expenditure | 2.08 | 50.0% |
| PBT | -8.09 | 978.7% |
| Net Profit | -8.09 | 978.7% |
| OPM | — | |
| NPM | — | |
| EPS | -0.69 | 666.7% |
Clene Reports Q1 2026 Financial Results and Operating Highlights
14 May 2026 · 14 May, 5:37 pm
Summary
Clene Inc. announced its first quarter 2026 financial results, highlighting progress with CNM-Au8 and recent financing activities. The company had a successful Type C meeting with the FDA and plans to submit an NDA for CNM-Au8 in Q3 2026. Clene completed multiple direct offerings, raising over $35 million. The company's cash and cash equivalents totaled $5.9 million as of March 31, 2026, and expects operating runway into the fourth quarter of 2026.
Key Highlights
- 1
Clene expects to submit an NDA for CNM-Au8® under the accelerated approval pathway in the third quarter of 2026.
- 2
Clene completed an oversubscribed registered direct offering totaling over $28 million in January 2026.
- 3
The company amended its existing $10 million convertible debt facility in May 2026, extending maturity to August 2027.
- 4
Clene completed a $7 million underwritten registered direct offering with a single investor in May 2026.
- 5
Cash and cash equivalents totaled $5.9 million as of March 31, 2026, compared to $5.2 million as of December 31, 2025.
- 6
Research and development expenses were $0.3 million for the quarter ended March 31, 2026, compared to $1.5 million for the same period in 2025.
- 7
Clene reported a net loss of $8.1 million, or $0.69 per share, for the quarter ended March 31, 2026, compared to a net loss of $0.8 million, or $0.09 per share, for the same period in 2025.
Management Comments
Rob Etherington
“We were encouraged by the constructive dialogue during our recent Type C meeting with the FDA and appreciate the Agency’s engagement as we advance toward a planned NDA submission for CNM-Au8 under the accelerated approval pathway for patients with ALS. People living with ALS continue to need additional treatment options, and we believe CNM-Au8 has the potential to restore and protect neuronal health and function, leading to improved survival. We look forward to continuing to work collaboratively with the FDA as the Agency reviews our extensive clinical efficacy and safety data.”
Informational and educational content only. Not investment advice.